These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22534780)

  • 1. Risk of non-melanoma cancers in first-degree relatives of CDKN2A mutation carriers.
    Mukherjee B; Delancey JO; Raskin L; Everett J; Jeter J; Begg CB; Orlow I; Berwick M; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Culver HA; Rosso S; Zanetti R; Kanetsky PA; From L; Gruber SB;
    J Natl Cancer Inst; 2012 Jun; 104(12):953-6. PubMed ID: 22534780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High risk of tobacco-related cancers in CDKN2A mutation-positive melanoma families.
    Helgadottir H; Höiom V; Jönsson G; Tuominen R; Ingvar C; Borg A; Olsson H; Hansson J
    J Med Genet; 2014 Aug; 51(8):545-52. PubMed ID: 24935963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Different Cancers Among First-degree Relatives of Pancreatic Cancer Patients: Influence of Probands' Susceptibility Gene Mutation Status.
    Antwi SO; Fagan SE; Chaffee KG; Bamlet WR; Hu C; Polley EC; Hart SN; Shimelis H; Lilyquist J; Gnanaolivu RD; McWilliams RR; Oberg AL; Couch FJ; Petersen GM
    J Natl Cancer Inst; 2019 Mar; 111(3):264-271. PubMed ID: 29982661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
    Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
    J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDKN2a mutation-negative melanoma families have increased risk exclusively for skin cancers but not for other malignancies.
    Helgadottir H; Höiom V; Tuominen R; Jönsson G; Månsson-Brahme E; Olsson H; Hansson J
    Int J Cancer; 2015 Nov; 137(9):2220-6. PubMed ID: 25943250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective risk of cancer in CDKN2A germline mutation carriers.
    Goldstein AM; Struewing JP; Fraser MC; Smith MW; Tucker MA
    J Med Genet; 2004 Jun; 41(6):421-4. PubMed ID: 15173226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling.
    McWilliams RR; Wieben ED; Rabe KG; Pedersen KS; Wu Y; Sicotte H; Petersen GM
    Eur J Hum Genet; 2011 Apr; 19(4):472-8. PubMed ID: 21150883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)-positive melanoma families.
    de Snoo FA; Bishop DT; Bergman W; van Leeuwen I; van der Drift C; van Nieuwpoort FA; Out-Luiting CJ; Vasen HF; ter Huurne JA; Frants RR; Willemze R; Breuning MH; Gruis NA
    Clin Cancer Res; 2008 Nov; 14(21):7151-7. PubMed ID: 18981015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Cancer Susceptibility Gene Mutations and ABO Blood Group of Pancreatic Cancer Probands on Concomitant Risk to First-Degree Relatives.
    Antwi SO; Rabe KG; Bamlet WR; Meyer M; Chandra S; Fagan SE; Hu C; Couch FJ; McWilliams RR; Oberg AL; Petersen GM
    Cancer Epidemiol Biomarkers Prev; 2022 Feb; 31(2):372-381. PubMed ID: 34782396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer risks in BRCA2 mutation carriers.
    Breast Cancer Linkage Consortium
    J Natl Cancer Inst; 1999 Aug; 91(15):1310-6. PubMed ID: 10433620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing a single SNP located at TERT/CLPTM1L multi-cancer risk region as a genetic modifier for risk of pancreatic cancer and melanoma in Dutch CDKN2A mutation carriers.
    Christodoulou E; Visser M; Potjer TP; van der Stoep N; Rodríguez-Girondo M; van Doorn R; Gruis N
    Fam Cancer; 2019 Oct; 18(4):439-444. PubMed ID: 31203567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the
    Middlebrooks CD; Stacey ML; Li Q; Snyder C; Shaw TG; Richardson-Nelson T; Rendell M; Ferguson C; Silberstein P; Casey MJ; Bailey-Wilson JE; Lynch HT
    Cancer Res; 2019 Jun; 79(11):2992-3000. PubMed ID: 30967399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
    Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
    J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histologic features of melanoma associated with germline mutations of CDKN2A, CDK4, and POT1 in melanoma-prone families from the United States, Italy, and Spain.
    Sargen MR; Calista D; Elder DE; Massi D; Chu EY; Potrony M; Pfeiffer RM; Carrera C; Aguilera P; Alos L; Puig S; Elenitsas R; Yang XR; Tucker MA; Landi MT; Goldstein AM
    J Am Acad Dermatol; 2020 Sep; 83(3):860-869. PubMed ID: 32283231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma risk for CDKN2A mutation carriers who are relatives of population-based case carriers in Australia and the UK.
    Cust AE; Harland M; Makalic E; Schmidt D; Dowty JG; Aitken JF; Agha-Hamilton C; Armstrong BK; Barrett JH; Chan M; Chang YM; Gascoyne J; Giles GG; Holland EA; Kefford RF; Kukalizch K; Lowery J; Randerson-Moor JA; Schmid H; Taylor CF; Whitaker L; Hopper JL; Newton-Bishop JA; Mann GJ; Bishop DT; Jenkins MA
    J Med Genet; 2011 Apr; 48(4):266-72. PubMed ID: 21325014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in Cutaneous Patterns of Melanomagenesis According to Germline CDKN2A/CDK4 Status in Melanoma-Prone Families.
    Sargen MR; Pfeiffer RM; Yang XR; Tucker MA; Goldstein AM
    J Invest Dermatol; 2020 Jan; 140(1):174-181.e3. PubMed ID: 31326397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status.
    Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V
    J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer risks and mortality in heterozygous ATM mutation carriers.
    Thompson D; Duedal S; Kirner J; McGuffog L; Last J; Reiman A; Byrd P; Taylor M; Easton DF
    J Natl Cancer Inst; 2005 Jun; 97(11):813-22. PubMed ID: 15928302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations.
    Potrony M; Puig-Butille JA; Aguilera P; Badenas C; Tell-Marti G; Carrera C; Javier Del Pozo L; Conejo-Mir J; Malvehy J; Puig S
    JAMA Dermatol; 2016 Apr; 152(4):405-12. PubMed ID: 26650189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pediatric melanoma in melanoma-prone families.
    Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA
    Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.